Concepedia

Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives

Y. Nagaoka, Taishi Maeda, Yuki Kawai, Daisuke Nakashima, Tadao Oikawa, Koji Shimoke, T. Ikeuchi, Hiroshi Kuwajima, Shinichi Uesato

European Journal of Medicinal Chemistry · 2006 · 42 citations · 16 references

DOI

Concepts

References

16

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked <i>in vivo</i> antitumor activity against human tumors

Akiko Saito, Takashi Yamashita, Yukiyasu Mariko et al. · Proceedings of the National Academy of Sciences · 1999 · 696 citations · Full text

, , +13

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor et al. · PubMed · 2003 · 623 citations

, , +16

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Victor Sandor, Susan Bakke, Robert W. Robey et al. · PubMed · 2002 · 510 citations

, , +12

FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor

Hidenori Nakajima, Young Bae Kim, Hiroshi Terano et al. · Experimental Cell Research · 1998 · 487 citations

, , +8

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

Richard Piekarz, Robert W. Robey, Victor Sandor et al. · Blood · 2001 · 447 citations · Full text

, , +11